What are the dental implications of using Prolia (denosumab) compared to teriparatide (recombinant PTH 1‑34)?

Dental Implications: Prolia (Denosumab) vs Teriparatide

Both Prolia (denosumab) and teriparatide carry risk of osteonecrosis of the jaw (ONJ), but denosumab poses significantly higher risk comparable to bisphosphonates, while teriparatide may actually promote healing of ONJ and carries minimal to no ONJ risk.

Osteonecrosis of the Jaw Risk Profile

Denosumab (Prolia)

• ONJ incidence in osteoporosis patients: 0.001% to 0.21% depending on duration of therapy 1
• Risk increases with duration of exposure, similar to bisphosphonates 1
• Higher doses used in oncology settings show 0.7-6.9% ONJ risk 2
• Tooth extraction while on denosumab carries approximately 0.5% risk of developing ONJ 1
• Cases of ONJ have been documented in patients exposed to denosumab, both alone and in sequence with bisphosphonates 3

Teriparatide

• No established causal relationship with ONJ 1, 3
• Case reports suggest teriparatide may actually promote healing of existing ONJ lesions 1
• Considered a safe option for osteoporosis treatment in patients who have already developed ONJ 3
• No cases of ONJ reported in clinical trials with teriparatide 3

Pre-Treatment Dental Management

Before Starting Denosumab

• Complete all invasive dental procedures before initiating therapy 2, 4
• Ideally delay denosumab initiation for 14-21 days after invasive dental work to allow wound healing 4
• Establish good oral hygiene: brushing and flossing after meals, fluoride mouth rinse 4
• Baseline dental evaluation for high-risk individuals 5

Before Starting Teriparatide

• No specific dental precautions required beyond routine care 6
• Standard oral hygiene maintenance sufficient

During Active Treatment

On Denosumab

• Avoid invasive dental procedures whenever possible 2, 4
• Maintain meticulous oral hygiene to prevent need for extractions 1
• If invasive dental surgery becomes necessary, do not discontinue denosumab per American Dental Association guidelines 1
• However, American Association of Oral and Maxillofacial Surgeons recommends considering a 2-month drug holiday if patient has been on therapy >4 years 1

Critical caveat: Stopping denosumab carries its own serious risk—rapid rebound in bone turnover with potential for multiple vertebral fractures within months 1, 7. This creates a clinical dilemma requiring careful risk-benefit assessment.

On Teriparatide

• Routine dental care without special restrictions 6
• May proceed with invasive dental procedures as clinically indicated
• No drug holiday required for dental work

Management of Established ONJ

If ONJ Develops on Denosumab

• Conservative management first: antibacterial mouth rinse for stage 0-2 ONJ 1
• Surgical debridement reserved for stage 3 ONJ 1
• Consider switching to teriparatide for dual benefit: continued osteoporosis treatment plus potential ONJ healing 3
• Multiple case reports show successful outcomes when switching from denosumab to teriparatide after ONJ diagnosis 3

If ONJ Develops on Teriparatide

• Extremely rare scenario given lack of established association
• Standard ONJ management protocols apply

Key Clinical Decision Points

For patients requiring extensive dental work:

• Teriparatide is the preferred choice if anabolic therapy is indicated 3
• Complete all dental procedures before starting denosumab if antiresorptive therapy is chosen
• Consider oral bisphosphonates over denosumab if dental issues are ongoing

For patients with history of ONJ:

• Teriparatide is strongly preferred over denosumab 3
• May actually promote healing of existing ONJ lesions 1
• Denosumab should be avoided or used with extreme caution

For patients on denosumab needing urgent dental extraction:

• Proceed with extraction if clinically necessary—do not delay needed care 1
• Optimize oral hygiene before and after procedure
• Close monitoring for ONJ development (exposed bone not healing >8 weeks) 2
• Do not routinely discontinue denosumab due to rebound fracture risk 1

Practical Algorithm

1. Pre-treatment dental assessment → Complete all invasive work before starting denosumab
2. Drug selection → If extensive dental disease or history of ONJ → Choose teriparatide over denosumab
3. During treatment → Denosumab patients avoid elective invasive procedures; teriparatide patients have no restrictions
4. If ONJ develops → Consider switching from denosumab to teriparatide for potential healing benefit 3

The fundamental difference is that denosumab behaves like bisphosphonates regarding ONJ risk, while teriparatide does not carry this risk and may even be therapeutic for ONJ 1, 3.